European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017 - MarketsandMarkets

European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017

European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017 - MarketsandMarkets
European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017
Published Jul 05, 2013
333 pages — Published Jul 05, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:

The European injectable drug delivery market was valued at $6.8 billion in 2012, and is expected to reach $12.4 billion by 2017 at a CAGR of 12.7% from 2012 to 2017. Injectable drug delivery technologies are a combination of two major segments - devices and formulations. The European injectable drug delivery formulations technologies market is the largest segment in the market. This is due to a surge of biologics and development of nanotechnologies. In addition, the market is segmented on the basis of its therapeutic applications. In the therapeutic field, hormonal disorders command the major segment due to the high demand of injectable in the treatment of diabetes.

The growth of the injectable drug delivery technologies market is primarily triggered by favorable reimbursement policies on injectable drugs and devices, technological advancements, surge of biologics in pharmaceutical markets, rising incidences of cancer and diabetes in Europe, and improving patient compliance. The evolving opportunities in this market for manufacturers include development of biosimilars in pharmaceutical markets and focus of pharmaceutical manufacturers towards emerging markets such as Spain, Russia, Denmark, Ireland and others. However, factors such as needle-stick injuries and infections and development of alternate delivery methods are restraining the growth of the market.

Germany accounted for the largest market share of the European injectable drug delivery market in 2012, followed by France. While Germany is a mature market experiencing a surge in biologics and high incidence of chronic diseases, France is the fastest-growing region. This is due to high insurance coverage for injectable devices and formulations, affordability for healthcare expenses, and activities such as exhibitions and conferences hosted by France that address injectable drug delivery technologies. The other European regions of Spain, Italy and Russia show high export potential for plastic syringes and needle, rising support for generics market, and increasing expenditure in the healthcare sector. The regions of Switzerland, Denmark, Ireland, Greece, Hungary, the Netherlands, Poland, Portugal, Romania, and Ukraine provide benefits such as favorable environment for research and development, growth in diabetic expenditures, and favorable reimbursement policies for injectable devices.

The key players in this market are Becton Dickinson & Co. (U.S.), Baxter International, Inc. (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Eli Lily & Co. (U.S.), Gerresheimer AG (Germany), Sanofi (France), West Pharmaceutical Services, Inc. (U.S.), Haselmeier GmbH (Germany), and Owen Mumford, Ltd. (U.K.).

Scope of the Report

This research report categorizes the European injectable drug delivery technologies market into two segments, namely, Europe injectable drug delivery devices technologies and European injectable drug delivery formulations technologies. These markets are broken down into segments and sub-segments, providing value analysis for 2010, 2011, and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed by geography (Germany, France, U.K., Spain, Italy, Russia and Rest of Europe (RoE)) to provide in-depth information on the European scenario.

Europe Injectable Drug Delivery Technologies Market, By Segment

Injectable Drug Delivery Devices Technologies
Injectable Drug Delivery Formulations Technologies
Europe Injectable Drug Delivery Devices Technologies Market, By Product

Conventional Injection Devices
By Materials
Glass
Plastics
By Products
Fillable Syringes
Prefilled Syringes
By Usability
Reusable
Disposable
Self-In

  
Source:
Document ID
BT 2073
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title
Table Of Contents

1 Introduction (Page No. - 26)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No. - 34)

3 Market Overview (Page No. - 39)
3.1 Introduction
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Technological Advancements
3.3.1.2 Favorable Reimbursement Environment To Bolster The Demand Of Self Injection Devices
3.3.1.3 Surge Of Biologics In European Pharmaceutical Market
3.3.1.4 Rising Incidences Of Cancer And Diabetes
3.3.1.5 Improving Patient Compliance
3.3.2 Restraints
3.3.2.1 Needle-Stick Injuries And Infections
3.3.2.2 Threat From Alternate Drug Delivery Methods
3.3.2.3 Slow Approval Process Of Drugs And Medical Devices In Europe
3.3.3 Opportunities
3.3.3.1 Development Of Biosimilars In The European Pharmaceutical Market
3.3.3.2 Need For Better Healthcare For The Increasing Geriatric Population Of Europe
3.3.4 Challenges
3.3.4.1 Sustainability Of Players In Highly Competitive Market
3.4 Market Share Analysis, By Major Players
3.4.1 Conventional Injectable Drug Delivery Devices
3.4.2 Self-Injection Devices-Pen Injectors

4 European Injectable Drug Delivery Devices Technologies Market (Page No. - 65)
4.1 Introduction
4.2 Market Segmentation
4.3 Manufacturers Criteria For Selection Of An Injectable Device
4.4 Conventional Injectable Drug Delvery Devices
4.4.1 By Usability
4.4.1.1 Disposable
4.4.1.2 Reusable
4.4.2 By Material
4.4.2.1 Glass
4.4.2.2 Plastic
4.4.3 By Product
4.4.3.1 Fillable
4.4.3.2 Prefilled
4.5 Self-Injection Devices
4.5.1 Market Segmentation
4.5.2 Selection Criteria For Self-Injection Device
4.5.3 Pen Injectors
4.5.3.1 By Product
4.5.3.1.1 Single Chamber Pen Injectors
4.5.3.1.2 Dual Chamber Pen Injectors
4.5.3.2 By Usability
4.5.3.2.1 Disposable Pen Injectors
4.5.3.2.2 Reusable Pen Injectors
4.5.3.3 By Design
4.5.3.3.1 Standard Pen Injectors
4.5.3.3.2 Customized Pen Injectors
4.5.4 Needle-Free Injectors
4.5.4.1 By Product
4.5.4.1.1 Prefilled Needle Free Injectors
4.5.4.1.2 Fillable Needle Free Injectors
4.5.4.2 By Technology
4.5.4.2.1 Jet-Based Needle-Free Injectors
4.5.4.2.2 Spring-Based Needle-Free Injectors
4.5.4.2.3 Laser-Based Needle Free Injectors
4.5.4.2.4 Vibration-Based Needle Free Injectors
4.5.4.3 By Usability
4.5.4.3.1 Disposable
4.5.4.3.2 Reusable
4.5.5 Auto Injectors
4.5.5.1 By Product
4.5.5.1.1 Prefilled Auto Injectors
4.5.5.1.2 Fillable Auto Injectors
4.5.5.2 By Technology
4.5.5.2.1 Automated Auto Injectors
4.5.5.2.2 Manual Auto Injectors
4.5.5.3 By Design
4.5.5.3.1 Standardized Auto Injectors
4.5.5.3.2 Customized Auto Injectors
4.5.5.4 By Usability
4.5.5.4.1 Disposable Auto Inj

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017" Jul 05, 2013. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/European-Injectable-Drug-Delivery-Market-By-Formulations-Liposomes-Microspheres-Nanoparticles-Devices-Disposables-Reusable-Fillable-Prefilled-Pen-Needle-Free-Auto-Injectors-Therapeutics-Diabetes-Oncology-Forecasts-to-2017-2144-178>
  
APA:
MarketsandMarkets. (2013). European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017 Jul 05, 2013. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/European-Injectable-Drug-Delivery-Market-By-Formulations-Liposomes-Microspheres-Nanoparticles-Devices-Disposables-Reusable-Fillable-Prefilled-Pen-Needle-Free-Auto-Injectors-Therapeutics-Diabetes-Oncology-Forecasts-to-2017-2144-178>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.